RTP Mobile Logo
RTP On Demand: Current Controversies and Emerging Data Sets in Breast Cancer
Released April 2014

Proceedings from a video interview with Dr Sunil Verma on breast cancer, including data review, case-based discussions and downloadable slides. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists, breast cancer surgeons, radiation oncologists and other healthcare providers involved in the treatment of breast cancer.

    Breast cancer is one of the most rapidly evolving fields in all of medicine. Results presented at the annual San Antonio Breast Cancer Symposium (SABCS) from a plethora of ongoing clinical trials lead to the continual emergence of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care, the practicing oncologist must be well informed of these advances. To bridge the gap between research and patient care, this program uses one-on-one discussion with Dr Sunil Verma about treatment controversies and the integration of key data sets recently presented at the 2013 SABCS into the practical management of breast cancer.


    • Apply the results of emerging clinical trial data to the best-practice care of patients with early and advanced breast cancer.
    • Appropriately use existing and novel biomarkers to assess risk and individualize therapy for patients with breast cancer.
    • Formulate a long-term clinical plan for the management of advanced hormone receptor-positive pre- and postmenopausal breast cancer, considering the use of endocrine, biologic and/or chemotherapeutic agents.
    • Identify existing and emerging rational systemic and targeted treatments for patients with HER2-positive and triple-negative breast cancer in the early and advanced settings.
    • Recall the design of ongoing clinical trials, and counsel eligible patients for study participation.


    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CME activity consists of a video component. The participant should watch the video.

    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and his spouse/partner) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Sunil Verma, MD, MSEd
    Medical Oncologist
    Chair, Breast Medical Oncology
    Head, Breast Cancer Clinical Trials
    Sunnybrook Odette Cancer Centre
    Associate Professor, University of Toronto
    Toronto, Ontario, Canada

    Advisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Eisai Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc; Speakers Bureau: Novartis Pharmaceuticals Corporation, Roche Laboratories Inc.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc, Teva Oncology and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc and Genomic Health Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: April 2014
    Expiration date: April 2015

Acknowledge and close

Watch video
(WIFI is recommended for best performance):

Adjuvant treatment with bisphosphonates
Adjuvant treatment with bisphosphonates
Removal of primary breast cancer in patients with metastases
Removal of primary breast cancer in patients with metastases
Triple-negative breast cancer (TNBC)
CALGB 40603: Addition of carboplatin and/or bevacizumab to neoadjuvant chemotherapy for TNBC
I-SPY data set on carboplatin and the PARP inhibitor veliparib
PARP inhibitors and BRCA testing
Sequencing of chemotherapy in metastatic TNBC
JAK amplification is associated with poor prognosis for patients with TNBC
SWOG S0500: A trial evaluating tailoring treatment based on circulating tumor cells in metastatic breast cancer
HER2-positive disease
Adjuvant therapy for node-negative, HER2-positive breast cancer
Meta-analysis of the randomized trastuzumab trials
BETH trial: Adjuvant chemotherapy with trastuzumab ± bevacizumab
Tumor-infiltrating lymphocytes
ER-positive breast cancer
Discordance between genomic-based assays for early breast cancer
Cost impact of the Oncotype® DX assay
Using a genomic assay to predict late distant recurrence after 5 years of endocrine therapy
Combining an AI and a TKI for postmenopausal women with metastatic ER-positive breast cancer
FALCON: Fulvestrant versus anastrozole in postmenopausal women with locally advanced or metastatic ER-positive breast cancer who have not previously received hormonal therapy